STO · FLUI.ST
Fluicell AB (publ)
SEK 27.70-SEK 0.10 (-0.36%)
Fluicell AB (publ)’s quoted price sits in the lower half of its reported 52-week range, 58.78% below the high.
Loading market information…
STO · LIDDS.ST · SEK
Stock price, earnings
Quote as of Feb 9, 2026, 02:00 PM UTC. Cached market data; not a live quote.
One-year closing-price history · SEK. Historical prices are not a forecast.
LIDDS AB (publ)’s quoted price sits in the lower half of its reported 52-week range, 87.7% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
BEHIND THE RESULTS
Upcoming dates and analyst estimates may change. Fiscal quarters follow LIDDS AB (publ)’s reporting calendar.
THE COMPANY BEHIND THE TICKER
LIDDS AB (publ), a pharmaceutical company headquartered in Uppsala, Sweden, specializes in the research, development, and marketing of therapeutic agents for cancer and various other medical conditions. The firm's innovative pipeline includes several drug candidates: NZ-2HOF is being advanced for prostate cancer; NZ-DTX targets a broad spectrum of malignancies such as breast, prostate, head, neck, stomach, and lung cancer; NZ-DOX is in development for solid tumors; NZ-IO represents an immunotherapy; NZ-STING focuses on immuno-oncology; and NZ-TLR9 aims to bolster cancer immunotherapies. Additionally, LIDDS AB (publ) maintains a collaborative partnership with PharmIdea SIA, concentrating efforts on anti-cancer medications and the creation of sterile drug formulations.
Latest available per-share figures in SEK. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 07:19 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
SEK 27.70-SEK 0.10 (-0.36%)
Fluicell AB (publ)’s quoted price sits in the lower half of its reported 52-week range, 58.78% below the high.
SEK 1.47SEK 0.00 (0.0%)
Guard Therapeutics International AB (publ)’s quoted price sits in the lower half of its reported 52-week range, 94.56% below the high.
SEK 0.21SEK 0.00 (0.0%)
Stayble Therapeutics AB (publ)’s quoted price sits in the lower half of its reported 52-week range, 68.27% below the high.
SEK 0.02-SEK 0.00 (-7.14%)
Gabather AB (publ)’s quoted price sits in the lower half of its reported 52-week range, 81.8% below the high.
SEK 0.42-SEK 0.06 (-12.13%)
2cureX AB (publ)’s quoted price sits in the lower half of its reported 52-week range, 87.16% below the high.
SEK 0.27SEK 0.00 (0.0%)
Aptahem AB (publ)’s quoted price sits in the lower half of its reported 52-week range, 86.21% below the high.
SEK 0.00+SEK 0.00 (+5.56%)
S2Medical AB (publ)’s quoted price sits in the lower half of its reported 52-week range, 74.67% below the high.
SEK 0.00-SEK 0.00 (-16.67%)
Quia Pharma AB (publ)’s quoted price sits in the lower half of its reported 52-week range, 98.33% below the high.
